Prostanoids in asthma and COPD actions, dysregulation, and th erapeutic opportunities

Chest

Volumn 148, Issue 5, 2015, Pages 1300-1306

  Zaslona, Zbigniew ^a   Peters Golden, Marc ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; PROSTACYCLIN; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTANOID; PROSTANOID RECEPTOR; THROMBOXANE A2; PROSTAGLANDIN;

ARTICLE; ASTHMA; BRONCHOCONSTRICTION; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; EMPHYSEMA; EOSINOPHIL; HUMAN; INFECTION SENSITIVITY; LYMPHOCYTE ACTIVATION; MESENCHYME CELL; NEUTROPHIL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; DISEASE MANAGEMENT; METABOLISM; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ASTHMA; DISEASE MANAGEMENT; EOSINOPHILS; HUMANS; PROSTAGLANDINS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84946615765     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.15-1029     Document Type: Article

References (67)

1. Claar D, Hartert TV, Peebles RS Jr. The role of prostaglandins in allergic lung inflammation and asthma. Expert Rev Respir Med. 2015; 9 (1): 55-72.
2. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science. 2001; 294 (5548): 1871-1875.
3. Huang SK, Peters-Golden M. Eicosanoid lipid mediators in fibrotic lung diseases: ready for prime time? Chest. 2008; 133 (6): 1442-1450.
4. Splawinski J, Gryglewski RJ. Release of prostacyclin by the lung. Bull Eur Physiopathol Respir. 1981; 17 (4): 553-569.
5. Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, Manganiello VC. Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov. 2014; 13 (4): 290-314.
6. Dekkers BG, Racké K, Schmidt M. Distinct PKA and Epac compartmentalization in airway function and plasticity. Pharmacol Ther. 2013; 137 (2): 248-265.
7. McGrath KW, Icitovic N, Boushey HA, et al; Asthma Clinical Research Network of the National Heart, Lung, and Blood Institute. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med. 2012; 185 (6): 612-619.
8. Szefler SJ, Martin RJ. Lessons learned from variation in response to therapy in clinical trials. J Allergy Clin Immunol. 2010;125: 285-292.
9. Pavord ID, Wisniewski A, Mathur R, Wahedna I, Knox AJ, Tattersfield AE. effect of inhaled prostaglandin E2 on bronchial reactivity to sodium metabisulphite and methacholine in patients with asthma. Thorax. 1991; 46 (9): 633-637.
10. Melillo E, Woolley KL, Manning PJ, Watson RM, O'Byrne PM. effect of inhaled PGE2 on exercise-induced bronchoconstriction in asthmatic subjects. Am J Respir Crit Care Med. 1994; 149 (5): 1138-1141.
11. Szczeklik A, Mastalerz L, Nizankowska E, Cmiel A. Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma. Am J Respir Crit Care Med. 1996; 153 (2): 567-571.
12. Sestini P, Armetti L, Gambaro G, et al. Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Am J Respir Crit Care Med. 1996; 153 (2): 572-575.
13. Gardiner PJ, Collier HO. Specific receptors for prostaglandins in airways. Prostaglandins. 1980; 19 (6): 819-841.
14. Nizankowska E, Sheridan AQ, Maile MH, et al. Bronchodilatory properties of 2-decarboxy-2-hydroxymethyl prostaglandin E1. Prostaglandins. 1985; 29 (3): 349-362.
15. Maher SA, Birrell MA, Belvisi MG. Prostaglandin E2 mediates cough via the EP3 receptor: implications for future disease therapy. Am J Respir Crit Care Med. 2009; 180 (10): 923-928.
16. Buckley J, Birrell MA, Maher SA, Nials AT, Clarke DL, Belvisi MG. EP4 receptor as a new target for bronchodilator therapy. Thorax. 2011; 66 (12): 1029-1035.
17. Majeski E, Hoskins A, Dworski R, Sheller JR. Iloprost inhalation in mild asthma. J Asthma. 2012; 49 (9): 961-965.
18. Ishiura Y, Fujimura M, Nobata K, Oribe Y, Abo M, Myou S. Prostaglandin I2 enhances cough reflex sensitivity to capsaicin in the asthmatic airway. Cough. 2007; 3: 2.
19. Ishiura Y, Fujimura M, Shiba Y, et al. Beraprost, a stable analog of prostacyclin, enhances cough reflex sensitivity to capsaicin in bronchitic patients. Exp Lung Res. 2014; 40 (10): 495-499.
20. Torres R, Picado C, de Mora F. The PGE2-EP2-mast cell axis: an antiasthma mechanism. Mol Immunol. 2015; 63 (1): 61-68.
21. Mizuno R, Kamioka Y, Kabashima K, et al. In vivo imaging reveals PKA regulation of ERK activity during neutrophil recruitment to inflamed intestines. J Exp Med. 2014; 211 (6): 1123-1136.
22. Sturm EM, Schratl P, Schuligoi R, et al. Prostaglandin E2 inhibits eosinophil trafficking through E-prostanoid 2 receptors. J Immunol. 2008; 181 (10): 7273-7283.
23. Idzko M, Hammad H, van Nimwegen M, et al. Inhaled iloprost suppresses the cardinal features of asthma via inhibition of airway dendritic cell function. J Clin Invest. 2007; 117 (2): 464-472.
24. Nataraj C, Th omas DW, Tilley SL, et al. Receptors for prostaglandin E(2) that regulate cellular immune responses in the mouse. J Clin Invest. 2001; 108 (8): 1229-1235.
25. Zasona Z, Okunishi K, Bourdonnay E, et al. Prostaglandin E2 suppresses allergic sensitization and lung inflammation by targeting the E prostanoid 2 receptor on T cells. J Allergy Clin Immunol. 2014; 133 (2): 379-387.
26. Zhou W, Blackwell TS, Goleniewska K, et al. Prostaglandin I2 analogs inhibit Th 1 and Th 2 effector cytokine production by CD4 T cells. J Leukoc Biol. 2007; 81 (3): 809-817.
27. Säfholm J, Manson ML, Bood J, et al. Prostaglandin E2 inhibits mast cell-dependent bronchoconstriction in human small airways through the E prostanoid subtype 2 receptor [published online ahead of print May 9, 2015]. J Allergy Clin Immunol. doi:10.1016/j.jaci.2015.04.002.
28. Kalinski P. Regulation of immune responses by prostaglandin E2. J Immunol. 2012; 188 (1): 21-28.
29. Zhou W, Goleniewska K, Zhang J, et al. Cyclooxygenase inhibition abrogates aeroallergen-induced immune tolerance by suppressing prostaglandin I2 receptor signaling. J Allergy Clin Immunol. 2014;134:698-705.
30. Aronoff DM, Canetti C, Peters-Golden M. Prostaglandin E 2 inhibits alveolar macrophage phagocytosis through an E-prostanoid 2 receptor-mediated increase in intracellular cyclic AMP. J Immunol. 2004; 173 (1): 559-565.
31. Aronoff DM, Peres CM, Serezani CH, et al. Synthetic prostacyclin analogs differentially regulate macrophage function via distinct analogreceptor binding specificities. J Immunol. 2007; 178 (3): 1628-1634.
32. Zhou W, Dowell DR, Huckabee MM, et al. Prostaglandin I2 signaling drives Th 17 differentiation and exacerbates experimental autoimmune encephalomyelitis. PLoS One. 2012; 7 (5): e33518.
33. Ahmadi M, Emery DC, Morgan DJ. Prevention of both direct and cross-priming of antitumor CD8 1 T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo. Cancer Res. 2008; 68 (18): 7520-7529.
34. Baratelli F, Lin Y, Zhu L, et al. Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4 1 T cells. J Immunol. 2005; 175 (3): 1483-1490.
35. Fedyk ER, Phipps RP. Prostaglandin E2 receptors of the EP2 and EP4 subtypes regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells. Proc Natl Acad Sci USA. 1996; 93 (20): 10978-10983.
36. Savla U, Appel HJ, Sporn PH, Waters CM. Prostaglandin E(2) regulates wound closure in airway epithelium. Am J Physiol Lung Cell Mol Physiol. 2001; 280 (3): L421-L431.
37. Liu X, Ostrom RS, Insel PA. cAMP-elevating agents and adenylyl cyclase overexpression promote an antifibrotic phenotype in pulmonary fibroblasts. Am J Physiol Cell Physiol. 2004; 286 (5): C1089-C1099.
38. Kohyama T, Liu X, Kim HJ, et al. Prostacyclin analogs inhibit fibroblast migration. Am J Physiol Lung Cell Mol Physiol. 2002; 283 (2): L428-L432.
39. Mori A, Ito S, Morioka M, et al. effects of specific prostanoid EP receptor agonists on cell proliferation and intracellular Ca(2 1) concentrations in human airway smooth muscle cells. Eur J Pharmacol. 2011; 659 (1): 72-78.
40. Lundequist A, Nallamshetty SN, Xing W, et al. Prostaglandin E(2) exerts homeostatic regulation of pulmonary vascular remodeling in allergic airway inflammation. J Immunol. 2010; 184 (1): 433-441.
41. Jain PP, Leber R, Nagaraj C, et al. Liposomal nanoparticles encapsulating iloprost exhibit enhanced vasodilation in pulmonary arteries. Int J Nanomedicine. 2014; 9: 3249-3261.
42. Gauvreau GM, Watson RM, O'Byrne PM. Protective effects of inhaled PGE2 on allergen-induced airway responses and airway inflammation. Am J Respir Crit Care Med. 1999; 159 (1): 31-36.
43. Hartert TV, Dworski RT, Mellen BG, Oates JA, Murray JJ, Sheller JR. Prostaglandin E(2) decreases allergen-stimulated release of prostaglandin D(2) in airways of subjects with asthma. Am J Respir Crit Care Med. 2000; 162 (2 pt 1): 637-640.
44. Huang SK, White ES, Wettlaufer SH, et al. Prostaglandin E(2) induces fibroblast apoptosis by modulating multiple survival pathways. FASEB J. 2009; 23 (12): 4317-4326.
45. Huang SK, Wettlaufer SH, Hogaboam CM, et al. Variable prostaglandin E2 resistance in fibroblasts from patients with usual interstitial pneumonia. Am J Respir Crit Care Med. 2008; 177 (1): 66-74.
46. Kolodsick JE, Peters-Golden M, Larios J, Toews GB, Th annickal VJ, Moore BB. Prostaglandin E 2 inhibits fibroblast to myofibroblast transition via E. prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation. Am J Respir Cell Mol Biol. 2003; 29 (5): 537-544.
47. Yamabayashi C, Koya T, Kagamu H, et al. A novel prostacyclin agonist protects against airway hyperresponsiveness and remodeling in mice. Am J Respir Cell Mol Biol. 2012; 47 (2): 170-177.
48. Hattori R, Shimizu S, Majima Y, Shimizu T. Prostaglandin E2 receptor EP2, EP3, and EP4 agonists inhibit antigen-induced mucus hypersecretion in the nasal epithelium of sensitized rats. Ann Otol Rhinol Laryngol. 2009; 118 (7): 536-541.
49. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol. 2003; 111 (5): 913-921.
50. Zhou W, Newcomb DC, Moore ML, Goleniewska K, O'Neal JF, Peebles RS Jr. Cyclooxygenase inhibition during allergic sensitization increases STAT6-independent primary and memory Th 2 responses. J Immunol. 2008; 181 (8): 5360-5367.
51. Kowalski ML, Pawliczak R, Wozniak J, et al. Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients. Am J Respir Crit Care Med. 2000; 161 (2 pt 1): 391-398.
52. Corrigan CJ, Napoli RL, Meng Q, et al. Reduced expression of the prostaglandin E2 receptor E-prostanoid 2 on bronchial mucosal leukocytes in patients with aspirin-sensitive asthma. J Allergy Clin Immunol. 2012; 129 (6): 1636-1646.
53. Jinnai N, Sakagami T, Sekigawa T, et al. Polymorphisms in the prostaglandin E2 receptor subtype 2 gene confer susceptibility to aspirin-intolerant asthma: a candidate gene approach. Hum Mol Genet. 2004; 13 (24): 3203-3217.
54. Ying S, Meng Q, Scadding G, Parikh A, Corrigan CJ, Lee TH. Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells. J Allergy Clin Immunol. 2006; 117 (2): 312-318.
55. Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med. 2009; 360 (23): 2445-2454.
56. Dagouassat M, Gagliolo JM, Chrusciel S, et al. The cyclooxygenase-2-prostaglandin E2 pathway maintains senescence of chronic obstructive pulmonary disease fibroblasts. Am J Respir Crit Care Med. 2013; 187 (7): 703-714.
57. Chilosi M, Poletti V, Rossi A. The pathogenesis of COPD and IPF: distinct horns of the same devil? Respir Res. 2012; 13: 3.
58. Montuschi P, Barnes PJ. Exhaled leukotrienes and prostaglandins in asthma. J Allergy Clin Immunol. 2002; 109 (4): 615-620.
59. Montuschi P, Kharitonov SA, Ciabattoni G, Barnes PJ. Exhaled leukotrienes and prostaglandins in COPD. Thorax. 2003; 58 (7): 585-588.
60. Chen Y, Chen P, Hanaoka M, Droma Y, Kubo K. Enhanced levels of prostaglandin E2 and matrix metalloproteinase-2 correlate with the severity of airflow limitation in stable COPD. Respirology. 2008; 13 (7): 1014-1021.
61. Togo S, Holz O, Liu X, et al. Lung fibroblast repair functions in patients with chronic obstructive pulmonary disease are altered by multiple mechanisms. Am J Respir Crit Care Med. 2008; 178 (3): 248-260.
62. Wilborn J, Crofford LJ, Burdick MD, Kunkel SL, Strieter RM, Peters-Golden M. Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E 2 and to express cyclooxygenase-2. J Clin Invest. 1995; 95 (4): 1861-1868.
63. Larsson-Callerfelt AK, Hallgren O, Andersson-Sjöland A, et al. Defective alterations in the collagen network to prostacyclin in COPD lung fibroblasts. Respir Res. 2013; 14: 21.
64. Renard SI. Proof-of-concept study to demonstrate inhibition of prostaglandin E (PGE) production and associated biological effects in the lower respiratory tract by ibuprofen. NCT02006576. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2013. https://clinicaltrials.gov/ct2/NCT02006576. Last updated February 13, 2015.
65. Chen Y, Hanaoka M, Chen P, Droma Y, Voelkel NF, Kubo K. Protective effect of beraprost sodium, a stable prostacyclin analog, in the development of cigarette smoke extract-induced emphysema. Am J Physiol Lung Cell Mol Physiol. 2009; 296 (4): L648-L656.
66. Peters-Golden M. Putting on the brakes: cyclic AMP as a multipronged controller of macrophage function. Sci Signal. 2009; 2 (75): pe37.
67. Christenson SA, Steiling K, van den Berge M, et al. Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015; 191 (7): 758-766.